Top Markets
#1 Pleasing Gold Pleasing Gold +1,501.14%
#2 PulseChain PulseChain +54.75%
#3 Ontology Gas Ontology Gas +34.63%
#4 Merlin's Seal BTC Merlin's Seal BTC +33.38%
#5 BOOK OF MEME BOOK OF MEME +29.72%
#6 ConstitutionDAO ConstitutionDAO +25.40%
#7 Collect on Fanable Collect on Fanable +24.53%
#8 Unit Pump Unit Pump +24.29%
#9 Pump.fun Pump.fun +24.29%
#10 Neiro Neiro +23.35%
Coin of the day
Pleasing Gold Pleasing Gold
설정
언어
한국어
통화
USD
테마
Molecure S.A. Molecure S.A.

Molecure S.A.

MOC
주식 순위 #26168
Operating as a biopharmaceutical firm in Poland, Molecure S.A. specializes in... Operating as a biopharmaceutical firm in Poland, Molecure S.A. specializes in the research, development, and commercialization of innovative therapies designed to combat neoplastic (cancer) and inflammatory conditions. The company's pipeline prominently features OATD-01, a chitotriosidase/acidic mammalian chitinase inhibitor that has successfully advanced through Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and sarcoidosis. Additionally, Molecure is progressing its YKL-40 program for cancer and fibrosis, OATD-02 for oncology applications, and a Deubiquitinase program. Established in 2012, this Warsaw-headquartered enterprise adopted the name Molecure S.A. in March 2022, having previously been known as OncoArendi Therapeutics S.A.
주가
$1.73
시가총액
$42.88M
변동 (1일)
2.16%
변동 (1년)
-18.85%
국가
PL
거래 Molecure S.A. (MOC)

카테고리

Healthcare
Molecure S.A. (MOC)의 P/B 비율
2026 기준 P/B 비율 TTM: 0
Molecure S.A.의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 0입니다. 2026년 말 기준 P/B 비율은 0였습니다.
Molecure S.A.의 P/B 비율 기록 (2026 ~ 2026)
매년 말 P/B 비율
연도 P/B 비율 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 P/B 비율
회사 P/B 비율 P/B 비율 차이 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US